CME vs. S&P Global: Which Financial Stock Is a Better Buy for 2027?
Choosing between CME Group (CME -0.45%) and S&P Global (SPGI +0.70%) involves weighing the world’s leading derivatives marketplace against the preeminent provider of credit ratings and financial data. Which is the better buy today?
Both companies are infrastructure giants in the financial world. CME processes trillions in trades, while S&P Global provides the ratings and analytics that keep capital flowing. Investors often look to these financial stocks for stability, but their business models offer different exposures to market volatility and economic growth.
The case for CME
CME Group operates the world’s leading derivatives marketplace, enabling clients to trade futures and options across asset classes like energy and agriculture. The company serves various participants among financial stocks, including central banks. It maintains a technology partnership with Google Cloud and a joint venture with Flutter Entertainment (FLUT +0.35%). In 2025, one company accounted for 12% of CME’s clearing and transaction fee revenue. Customer concentration like this adds a layer of risk to the business.
In fiscal 2025, revenue reached nearly $6.5 billion, representing growth of roughly 6.4% over the previous year. Net income was close to $4 billion. The net margin was approximately 62%, which shows the percentage of revenue remaining after all operating and non-operating costs are paid.
As of CME’s December 2025 balance sheet, the debt-to-equity ratio is roughly 0.1. This ratio measures total debt relative to shareholders’ equity, indicating a very low reliance on borrowed funds. The current ratio, which compares short-term assets to short-term liabilities, is approximately 1. Free cash flow reached nearly $4.2 billion, representing the cash remaining after the company pays for its capital expenditures.
The case for S&P Global
S&P Global provides essential credit ratings, benchmarks, and analytics that facilitate global capital and commodity markets. Its business is highly diversified, with segments ranging from market intelligence to mobility and energy data. The company serves a global customer base including asset managers and automotive manufacturers through both third-party and proprietary distribution channels. This broad reach ensures its ratings and indexes remain standard tools for investors worldwide.
In fiscal 2025, revenue reached nearly $15.3 billion, representing growth of close to 7.9% over the prior year. Net income was approximately $4.5 billion. The net margin was roughly 29.2%, indicating that the company retains nearly $0.30 of profit for every dollar of revenue generated.
On S&P Global’s December 2025 balance sheet, the debt-to-equity ratio was approximately 0.5. The current ratio is roughly 0.8. Free cash flow for the period was close to $5.5 billion.
Expand
CME & SPGI: Performance Comparison
CME – CME Group
$304.52
–0.45% (-$1.37)
SPGI – S&P Global
$471.09
+0.70% (+$3.29)
Key Financial Metrics
CME – CME Group
$304.52
–0.45% (-$1.37)
SPGI – S&P Global
$471.09
+0.70% (+$3.29)
Market Cap
$109B
52wk Range
$218.31 – $322.82
Gross Margin
82.76%
P/E Ratio
24.97
EPS (TTM)
$12.20
Dividend & Yield
$5.15 (1.68%)
Market Cap
$137B
52wk Range
$360.94 – $522.35
Gross Margin
63.91%
P/E Ratio
28.02
EPS (TTM)
$16.81
Dividend & Yield
$3.87 (0.79%)
CME – CME Group
$304.52
–0.45% (-$1.37)
Market Cap
$109B
52wk Range
$218.31 – $322.82
Gross Margin
82.76%
P/E Ratio
24.97
EPS (TTM)
$12.20
Dividend & Yield
$5.15 (1.68%)
SPGI – S&P Global
$471.09
+0.70% (+$3.29)
Market Cap
$137B
52wk Range
$360.94 – $522.35
Gross Margin
63.91%
P/E Ratio
28.02
EPS (TTM)
$16.81
Dividend & Yield
$3.87 (0.79%)
Risk profile comparison
CME Group faces risks from global economic and political conditions that can significantly impact trading volumes. The company is subject to intense competition from other exchanges, over-the-counter markets, and digital asset platforms. Regulatory and compliance risks are also high, including potential new transaction taxes and oversight of prediction market activities. Operational risks include heavy reliance on third-party providers such as Google Cloud and the potential failure of clearing firms.
S&P Global faces significant cybersecurity and technology risks as a central provider of market data. The business is sensitive to interest rate fluctuations and market volatility, which can reduce the volume of new debt issuance. Competitive risks come from both traditional and non-traditional data providers, while regulatory oversight of credit rating agencies remains intense. It also faces operational risks from its reliance on third-party infrastructure providers such as Amazon (AMZN +2.94%) and the complexity of its planned segment separations.
Valuation comparison
CME Group has a lower forward P/E based on future earnings estimates, while S&P Global maintains a lower P/S ratio, which measures market value against sales over the past 12 months.
MetricCME GroupS&P GlobalForward P/E24.826.3P/S ratio15.88.6
Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy for 2027?
CME Group’s revenue growth is pretty uninspiring, but S&P Global’s isn’t significantly higher. Furthermore, CME pays a higher-yielding dividend. But I think the most attractive thing about the derivatives specialist is its net margin. CME’s 62% net margin is basically twice what S&P Global reported in fiscal 2025.
Now, let’s turn to the tape:
Past performance is no indication of future results, of course. But CME Group stock has trailed S&P Global by more than 100 percentage points over the past 10 years. Indeed, CME hasn’t even kept pace with the S&P 500.
An impressive net margin and a modest dividend are nice, but ultimately I want a stock that will increase in value. (Pretty core investing concept!) If CME Group hasn’t beaten the market over the past decade, why should I have any expectation that trend will reverse itself now? S&P Global gets my vote here.
Source: www.fool.com — article syndicated from the publisher’s feed; all rights remain with the original publisher.